CLINICO-BIOLOGICAL CHARACTERIZATION, THERAPEUTIC MANAGEMENT, AND OUTCOMES OF EXTRANODAL DIFFUSE LARGE B-CELL LYMPHOMA OF THE HEAD AND NECK: A REAL-WORLD MONOCENTRIC COHORT ANALYSIS (SIE 2026) - Oct 6, 2026 - Abstract #SP088; "Re- garding treatments, R-CHOP and R-miniCHOP yielded excel- lent results (CR/OS 84.6% and 80%, respectively), whereas R-DA-EPOCH was limited by toxicity (CR/OS 50%)...While CNS prophylaxis is effective and standard/adapted regimens offer good initial outcomes, the low PFS and dismal prognosis for RR patients highlight that primary chemo-resistance remains the main challenge. Early integration of innovative immunotherapies is essential for this fragile population"
Clinical • IO biomarker • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Head and Neck Cancer • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • BCL2 • BCL6 • MYC
|
|
M. Draisci; R. Marcolin; S. Franceschetti; S. Marinoni; A. Corso
|